Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Johnson & Johnson's PN-235?
PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis...